Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Oklahoma Medical Research Foundation study finds new MS biomarkers

Working with a team of international researchers, Oklahoma Medical Research Foundation scientist Robert Axtell has completed a study to identify patient responses to different MS therapies. [PHOTO PROVIDED]

In new research from the Oklahoma Medical Research Foundation, scientists have discovered subtle biological signs in the development of multiple sclerosis that point to the need for highly individualized treatment plans for patients suffering from the disease.

MS damages the nervous system's ability to carry signals to and from the brain. The disease can cause a wide variety of symptoms, including problems with vision, tremors, paralysis, muscle spasms, imbalance and cognitive changes.

Working with a team of international researchers, OMRF scientist Robert Axtell, Ph.D., completed a study to identify patient responses to different MS therapies, including the popular treatment interferon-beta. The findings were published in the journal Neurology, Neuroimmunology & Neuroinflammation.

According to Axtell, the wide range of patient responses to medications is one of the biggest hurdles in treating MS, as the disease can be caused or affected by a variety of factors. Researchers measured 50 immune molecules in the blood and found that certain subsets of MS patients responded well to standard treatments, while others did not.

“We looked for biomarkers that indicated the presence of disease, because they can help us identify which patients respond to specific therapies,” Axtell said. “We collaborated with a lot of folks and received blood samples and clinical data from a sizable MS patient population. It took a lot of effort from many clinical and basic scientists to complete this study.”

By knowing which biomarkers are associated with specific reactions or responses to certain drugs, scientists will have a better idea of how individual patients will respond to specific types of therapy, Axtell said.

“Our study definitely showed us that MS is not biologically the same in every patient, and that lets us know that a personalized approach is needed when it comes to treatment.”

How biomarkers help

Dr. Harold Hegen, of the Medical University of Innsbruck, Austria, who collaborated with Axtell on the study, believes the research provides helpful information to guide patient treatment.

“Given the large and increasing number of disease-modifying treatments for MS, there is a strong clinical need for biomarkers that enable treatment allocation in the individual patient,” Hegen said. “In the present study, we observed that MS patients can be grouped by specific patterns, which were predictive for response to interferon-beta therapy.”

Axtell said these results may eventually help scientists use these immune molecules as a predictive test for MS.

“We need to do many other studies to verify the molecules and refine the testing before this can be taken forward commercially,” Axtell said. “But this research lays the groundwork for developing tests for prediction of MS or patient treatment options for the disease.”

OMRF scientists Christopher Lessard, Ph.D., and Indra Adrianto, Ph.D., also contributed to the work, which was supported by grants from the National Institute of Neurological Disorders and Stroke and the National Institute of General Medical Science, both a part of the National Institutes of Health.

Ryan Stewart is media relations coordinator for Oklahoma Medical Research Foundation.

Story Source: The above story is based on materials provided by NEWSOK
Note: Materials may be edited for content and length

Go to Newer News Go to Older News